Kornimate/medical-research-clean huggingface dataset:
low-dose dobutamine tc-99m-mibi gated spect to predict left ventricular remodelling in patients reperfused in the acute phase of mi

Conditions: Ischemic Heart Disease; Myocardial Infarction

Summary: left myocardial infarction (mi), has a negative impact of long term morbidity and mortality. even in patients treated successfully by angioplasty in the acute phase of infarct, the remodelling is observed in approximately 30% of cases. it is important to predict the occurrence of this phenomenon in the early phase after mi for the selection of patients who could eventually benefit from new therapeutic approach as for example cell replacement therapy. it has been advocated that stem cells coronary injections should be performed between the 5th and 10th day after an acute event. we hypothesise that a low dose dobutamine gated tc-99m-mibi spect performed on 5th-6th day after reperfused acute mi can predict left ventricular remodelling and serve as a method to screen patients who could benefit from cell replacement therapy.

all patients will be evaluated by ce-mri during the initial hospital stay (5th - 6th day) and at 6-month follow-up. left ventricular remodelling will be defined as an end-diastolic volume increase of \>20% between the two exams. a low dose dobutamine gated tc-99m-mibi spect will be also performed on 5th-6th day. differences in the infarct size and severity as well as the residual inotrope reserve in the infarct area are expected between groups with and without remodelling.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction, * successful coronary angioplasty in the acute phase, * absence of heart failure in the acute phase exclusion criteria: * acute heart failure in the acute phase * severe ventricular arrhythmias * contra indications for mri imaging

Keywords: acute myocardial infarction left ventricular remodelling spect imaging
intralesional cemiplimab for adult patients with cutaneous squamous cell carcinoma or basal cell carcinoma

Conditions: Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma

Summary: this study is researching an experimental drug called cemiplimab. the study is focused on cutaneous squamous cell carcinoma (cscc) and basal cell carcinoma (bcc). the aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as regn2810). the first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. the study is also looking at several other research questions, including: * what side effects may happen from taking the study drug * to see effect of cemiplimab on the tumor * how much study drug is in the blood at different times


Eligibility criteria:
key inclusion criteria 1. dose escalation: history of recurrent resectable cscc or bcc (cohort c and i only) that satisfies conditions as defined in the protocol 2. patients must have measurable disease in the index lesion, defined as 1-2 cm in the longest diameter 3. eastern cooperative oncology group (ecog) performance status ≤1 key exclusion criteria 1. ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-mediated adverse events (imaes) 2. prior treatment with an agent that blocks the programmed cell death 1 (pd-1)/ programmed cell death 1 ligand (pd-l1) pathway. 3. prior treatment with other systemic immune modulating agent as defined in the protocol 4. m1 or n1, n2 (a, b, or c), or n3 cscc or bcc. patients with history of metastatic cscc (distant or nodal), or metastatic bcc (distant or nodal) are excluded unless the disease-free interval is at least 3 years 5. concurrent malignancies, other than those with negligible risk of metastasis or death. patients with hematologic malignancies, including chronic lymphocytic leukemia (cll), are excluded. 6. patients with a history of solid organ transplant 7. has received a coronavirus induced disease of 2019 (covid-19) vaccination (initial series and booster) within 1 week of planned start of study medication note: other protocol defined inclusion/exclusion criteria apply.

Keywords: cscc bcc
outcome of the treatment of flexor tendon injuries

Conditions: Finger Injuries; Tendon Injury - Hand

Summary: in order to gather enough data for meaningful statistics, a multicenter register of all flexor tendon repairs was established with surgical, clinical and rehabilitation patient data. the controlled active motion (cam) protocol was administered in all patients after surgery. the purpose was to (i) measure surgery and therapy outcomes in the three centers and (ii) evaluate potential influencing factors on outcomes.


Eligibility criteria:
inclusion criteria: * injury between 2014 and 2025 * flexor tendon injury of the fingers or thumb in zones 1-3 exclusion criteria: * no given consent * concomitant injuries as fractures, large soft tissue injuries, replantation * bony avulsion fracture of flexor tendon (jersey finger) * basic disease as rheumatoid diseases * primary and secondary tendon reconstruction and tendon transfer

Keywords: tendon injuries flexor tendons
ischemic stroke nutrition intervention study

Conditions: Ischemic Stroke

Summary: the primary goal of this clinical trial is to assess whether vitamin k2 or zinc supplementation can effectively improve skeletal muscle and neurological function in patients with ischemic stroke. the main questions it aims to answer are: 1. does supplementation with vitamin k2 or zinc improve the subjects' muscle strength and muscle mass? 2. can supplementation with vitamin k2 or zinc improve the subjects' neurological function after a stroke? researchers will compare vitamin k2 or zinc supplements with a placebo to observe whether vitamin k2 or zinc supplementation can improve skeletal muscle and neurological function in patients with ischemic stroke. participants will: 1. take vitamin k2 (mk-7), zinc supplements, or a placebo daily for 2 years. 2. attend face-to-face visits and provide biological samples and relevant data at 0, 3, 6, 9, 12, and 24 months (intervention phase). after the intervention, follow-up will continue for 1 year to observe the long-term effects.


Eligibility criteria:
inclusion criteria： participants who meet all the following conditions will be included in the trial: 1. men or women aged ≥ 18 years. 2. patients with recent ischemic stroke（first or recurrent stroke no more than 7 days before admission）without significant residual limb paralysis, nihss score between 2-15, and muscle strength graded 2-4. 3. the patient and their legal guardian (or legally acceptable representative) voluntarily sign the informed consent form. exclusion criteria： participants who meet any of the following conditions will be excluded from the trial: 1. presence of consciousness disorders, aphasia, or swallowing disorders. 2. the diagnosis or suspicion of cerebral hemorrhage, atrial fibrillation, or other factors leading to cardiogenic cerebral infarction. 3. coagulation dysfunction or use of vitamin k antagonists. 4. suffering from chronic gastrointestinal malabsorption (such as celiac disease, short bowel syndrome), severe congestive heart failure, malignant hypertension, severe liver and kidney dysfunction, persistent malignant tumors (continuous treatment, or diagnosis of malignant tumors\<5 years), or other related diseases considered by researchers that seriously affect the patient's survival. 5. having musculoskeletal diseases or cognitive impairment before the stroke. 6. currently using or planning to use non research approved dietary supplements during the study period. 7. currently using or planning to use drugs that affect cognitive or neurological function during the research period. 8. restricted normal eating or currently receiving enteral or parenteral nutrition support. 9. contraindications for mri and other examinations. 10. currently pregnant or planning pregnancy, currently breastfeeding. 11. participated in a clinical trial using experimental drugs or devices within the past 3 months.

Keywords: vitamin k2 zinc skeletal muscle neurological function ischemic stroke
enhanced diagnostics for early detection of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: paroxysmal atrial fibrillation can only be diagnosed during episodes when the arrhythmia is present. the investigators hypothesize that the activation of the atrial myocardium resulting in the p-wave of the ecg should display abnormalities in diseased atria which are vulnerable for af.

in the first part of this trial different diagnostic techniques to detect arrythmogenic substrates of atrial fibrillation will be tested. if suitable parameters can be identified, a follow up trial to identify patients at risk for af will be conducted before a stroke happens. parameters tested are 1. electrophysiological differences between patients with paroxysmal af and no history of af 2. "vascular stiffness" detected by an iphone app all patients will undergo a cardiogoniometrie and a pulse wave analysis with an iphone. each exam takes 5 minutes.

Eligibility criteria:
inclusion criteria: * paroxysmal atrial fibrillation in sinus rhythm at presentation exclusion criteria: * acute cerebral trauma * antiarrhythmic medication

Keywords: atrial fibrillation atrial electrophysiology stroke vascular stiffness
the role of colchicine in reducing the rate of myocardial reperfusion injury

Conditions: Reperfusion Injury, Myocardial

Summary: the goal of this clinical trial is to investigate the role of colchicine in reducing the rate of myocardial reperfusion injury in patients with st-elevation myocardial infarction after primary percutaneous coronary intervention. the main questions it aims to answer are: * does colchicine reduce the rate of myocardial reperfusion injury ? * does colchicine reduce the concentration of markers of myocardial reperfusion injury (nlrp3, asc, caspase, and troponin) ? participants will * be grouped into intervention group and control group blindly. patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days. patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days. * undergo peripheral blood vein examination before primary percutaneous coronary intervention, after primary percutaneous coronary intervention, 24 hour after primary percutaneous coronary intervention, and 48 hour after primary percutaneous coronary intervention. researchers will compare intervention group and control group to see if colchicine reduces the rate of myocardial reperfusion injury and reduces the concentration of markers of myocardial reperfusion injury (nlrp3, asc, caspase, and troponin) in patients with st-elevation myocardial infarction after primary percutaneous coronary intervention.


Eligibility criteria:
inclusion criteria: * patients diagnosed with st-elevation myocardial infarction based on clinical symptoms, signs, and electrocardiography who undergo primary percutaneous coronary intervention * patients aged 18 - 80 years old exclusion criteria: * patients with malignancy * patients with allergic reaction to colchicine * stroke within the last 3 months * severe infection (sepsis) * chronic kidney disease with egfr of \<30ml/min/1.73m2

Keywords: myocardial reperfusion injury colchicine
the use of liraglutide in brain death

Conditions: Brain Death

Summary: there is evidence of the association of brain death and inflammation, affecting outcomes of transplanted organs, but in a way not fully understood. observational studies suggest that the use of target-guided therapies has a beneficial effect in reducing the rate of donor loss due to cardiac arrest and increasing the rate of donor-picked organs, which will be tested through the randomized clinical trial. however, no study so far has directly tested the effect of drugs with anti-inflammatory and anti-apoptotic properties administered to the donor in encephalic death in reducing inflammation of organs to be transplanted. this study aims to evaluate the use of liraglutide in patients with brain death in relation to their ability to attenuate the inflammation induced by encephalic death by means of a randomized clinical trial.

the intervention group will be composed of individuals deceased in brain dead, after the conclusion of the brain dead protocol by the teams responsible for the intensive care and will receive liraglutide. the control group will be composed of the same population of individuals who died in brain dead of the intervention group, but will receive a placebo.

Eligibility criteria:
inclusion criteria: * individuals deceased more than 18 years after the end of the brain death protocol exclusion criteria: * pregnant women, patients with advanced renal failure on hemodialysis, with hepatic insufficiency or allergy known to liraglutide

Keywords: liraglutide brain death inflammation
safety and effectiveness of biotraceio lite for tissue damage assessment following liver tissue ablation procedures

Conditions: Carcinoma, Hepatocellular; Metastatic Liver Cancer

Summary: clinical study planned to demonstrate that the biotraceio lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (t=24hrs) cect scan and that it is safe, based on an assessment of device-related adverse events. multi-center (up to 6 investigational sites) prospective single-arm clinical investigation 50 evaluable subjects total stratified by cancer type (primary hepatocellular carcinoma vs. secondary liver metastases).

clinical study planned to demonstrate that the biotraceio lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (t=24hrs) contrast-enhanced ct scan and that it is safe, based on an assessment of device-related adverse events. biotraceio lite is intended to provide physicians with adjunctive information in their clinical assessment of tissue damage created by liver tissue ablation, as part of their overall post-procedure clinical assessment. multi-center (up to 6 investigational sites) prospective single-arm clinical investigation 50 evaluable subjects total stratified by cancer type (primary hepatocellular carcinoma vs. secondary liver metastases).

Eligibility criteria:
inclusion criteria: 1. scheduled and indicated for standard-of-care liver tissue ablation for either hepatocellular carcinoma (hcc) or metastatic liver tumor(s) using either rf or mw energy. 2. at least 21 years of age 3. single tumor, or multiple tumors only if the distance between the ablated tumor and all other tumors allows for distinct separation between the necrotic zones (minimum of 1cm), based on the physician's discretion. 4. distance between the tumor and the edge of any previous necrotic zones allows for distinct separation between the necrotic zones (minimum of 1cm), based on the physician's discretion. 5. single ablation, using a single ablation needle, per tumor. 6. able and willing to give informed consent. exclusion criteria: 1. liver tumor that cannot be ablated with a single ablation needle, according to the investigator's clinical opinion. 2. subject cannot tolerate/undergo contrast-enhanced ct. 3. planned ablation includes adjunctive means other than rf or mw energy (e.g., ethanol, hepatic artery embolization, etc.) or overlapping ablations using a single ablation needle. 4. ablation area cannot be visualized continuously using ultrasound throughout the entire ablation procedure. 5. pregnant or lactating 6. currently participating in another clinical trial of an unapproved investigational device or drug that has not concluded the follow-up period. 7. unable or unwilling to give informed consent.
imaging with a radio tracer to guide vt ablations

Conditions: Ventricular Tachycardia; Arrhythmia

Summary: some patients are at risk for life-threatening fast heart rates. these can frequently be treated by using a catheter inside the heart to burn away the cells that create the fast heart rates. the purpose of this study is to image the nerves inside the heart of those patients. the investigators want to find out if abnormalities in the nervous system in the heart can help the physician to find the area that needs to be burnt away.

ventricular tachycardia is the next frontier in cardiology. patients that have scar in the heart (for example after heart attacks) are at an increased risk of developing ventricular tachycardia. in these patients ventricular tachycardia represents an electrical wave front that circulates in the heart muscle using the scar in the heart. an increasing number of patients with ventricular tachycardia require cauterization (burning away) of the tissue to treat this life-threatening condition. the goal of this cauterization or ablation is to destroy "highways of surviving tissue" inside the scar, that allow ventricular tachycardia to exist. however, this can be very lengthy procedure (\>5 hours) that has only a moderate success in the long run. therefore, new treatment approaches are needed to make this procedure better. the purpose of this study is to assess if radio tracers showing the nerve distribution in the heart (cardiac innervation) can be used in addition to the current technology ("voltage mapping") to identify the area that needs to be ablated (burnt away) to treat life-threatening fast heart rates (ventricular tachycardia) certain patterns of nerve distribution in the heart (sympathetic cardiac innervation) have been shown to predict outcome for different heart diseases, like heart transplant, coronary artery disease, heart failure, arrhythmias. one substance that allows visualization of the cardiac innervation is 123i-metaiodobenzylguanidine (123i-mibg), which could provide additional information to understand and treat ventricular tachycardia.

Eligibility criteria:
inclusion criteria: * patients with ventricular arrhythmias requiring vt ablation * patients must be 18 years of age or older * patient must be able to sign consent form * patient must be willing to come back for the 6 month visit for additional study procedures exclusion criteria: * patient under 18 years old * inability to sign consent * pregnant women

Keywords: ablation arrythmia imaging
periodization resistance training on quality of life in females with hypothyroidism

Conditions: Hypothyroidism

Summary: this study will be conducted to compare between the effect of nonlinear and linear periodized training on quality of life in females with hypothyroidism.

worldwide, the incidence of individuals with thyroid dysfunction is increasing and represents approximately 30-40% of the patients seen in an endocrine clinic; thus, it is one of the leading endocrine disorders.the undiagnosed thyroid dysfunction especially subclinical and clinical hypothyroidism may increase cardiovascular risk factors. the prevalence of hypothyroidism depends on many factors, such as age, sex and geographical factors. it's also a diet related disorder and it's usually seen when the daily intake of iodine falls below 25μg. hypothyroidism tends to affect women more often than men and can manifest at any age, typically observed between 40 and 70 years. no specific racial predilection has been identified in studies regarding this condition. regular exercise can improve quality of life in patients with subclinical hypothyroidism by increasing physical activity level/fitness and reducing the signs and symptoms of the disease. exercise may therefore potentiate the effectiveness of levothyroxine and help hypothyroid individuals improve their quality of life. periodization of resistance training or planned changes in training volume and intensity are used to maximize strength and fitness gains. the most common of periodized resistance training plans is linear also termed classic or strength/power periodization and nonlinear periodization. the biggest difference between these two types of training plans is with nonlinear periodization changes in training volume and intensity are made more frequently. the most common type of nonlinear periodization is daily nonlinear periodization where substantial changes in training intensity and volume are made from one training session to the next training session. so, this study will be conducted to compare between the effect of non linear and linear periodized resistance training on quality of life in females with hypothyroidism.

Eligibility criteria:
inclusion criteria: * be controlled hypothyroidism (tsh level within 0.5 - 4.5 mu/l) * be ranged from 35 to 45 years * female patients * body mass index 30-34.9 kg/m2 . * triglyceride-glucose (tyg) index \> 4.5 exclusion criteria: * history of pulmonary disease * patients with uncontrolled coronary or cerebrovascular disease * those who underwent musculoskeletal surgery within the previous year * recent history of lower and upper limb fracture , hip and shoulder dislocation. * cognitive impaired patients * patients with history of epilepsy * patients who participating in any other exercise program
anti covid-19 antibodies in follicular fluid and spermatic fluid

Conditions: SARS-CoV-2

Summary: patients going through an in vitro fertilization cycle will be asked to participate . patients will be asked for their covid-19 exposure : post confirmed disease/post vaccine/not exposed to disease or vaccine . patients will provide the fluids which are not required , once fertilization process is completed. patients will also provide 5ml blood sample by the day of procedure. anti covid-19 immunoglobulin g type antibodies will be measured in all samples . data regarding age, date of infection/vaccine will be collected . progesterone and estrogen will be measured in female patients' samples and perlecan level will be measured in follicular fluid.

patients going through an in vitro fertilization cycle will be asked to participate . patients will be asked for their covid-19 exposure : post confirmed disease/post vaccine/not exposed to disease or vaccine . patients will provide the fluids which are not required in the day of egg retrieval : the follicular fluid remaining after isolation of the egg and spermatic fluid only, if not utilized for fertilization. the fluids will be collected once fertilization process is completed. patients will also provide 5ml blood sample by the day of procedure. anti covid-19 immunoglobulin g type antibodies will be measured in all samples . data regarding age, date of infection/vaccine will be collected as well as indication for treatment, estradiol level before the egg retrieval, number of eggs collected and the triggering ovulation modality . progesterone and estrogen will be measured in female patients' samples (follicular fluid and serum). perlecan level will be measured in follicular fluid.

Eligibility criteria:
inclusion criteria: * planned egg retrieval procedure (including egg preservation) * negative pcr for sars-cov-19 in the week before egg retrival * informed consent exclusion criteria: * positive pcr for sars-cov-19 in the week before egg retrival * expected retrival of 1-3 eggs

Keywords: infertility; sars-cov-2,covid-19